Redhill Biopharma (STU:2RH) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma 5-Year Yield-on-Cost %?

Redhill Biopharma STU:2RH 18 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 513 Drug Manufacturers companies, Redhill Biopharma ranks worse than 194931.58% on this metric.

Redhill Biopharma's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Redhill Biopharma's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:2RH's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.29
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Redhill Biopharma  (STU:2RH) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Redhill Biopharma 5-Year Yield-on-Cost % Related Terms

STU:2RH vs SBFM, PRFX, CTTH: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's 5-Year Yield-on-Cost % falls into.


STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redhill Biopharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Redhill Biopharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Redhill Biopharma (STU:2RH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Redhill Biopharma's 5-Year Yield-on-Cost % too high?
Redhill Biopharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Redhill Biopharma ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's 5-Year Yield-on-Cost % compare to SBFM and PRFX?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #999999 out of 513 companies for 5-Year Yield-on-Cost %. This places Redhill Biopharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price